This milestone underscores Kerry’s growing role as a key innovator in the global enzyme market, combining deep biotechnology capabilities with integrated application expertise to solve pressing customer challenges across the food and beverage, biopharma and biotech sectors.
Foodservice, snacks and beverages supported growth across Kerry’s regions, while its Accelerate 2.0 programme helped drive a 50-basis-point improvement in EBITDA margin.
Strong Americas and APMEA growth offset subdued European market conditions.
The new centre, located within Kerry’s existing Medellín campus, provides a dedicated environment for customers and strategic partners to move rapidly from concept ideation to testing and prototyping, shortening development cycles for food and beverage solutions.
The agreement represents a significant milestone in Kerry’s continued growth across the Middle East and underscores the company’s commitment to driving food and beverage innovation in one of the world’s most dynamic markets.